Although several inhibitors targeting EGFR, MAPK, FAK1 or PI3K/Akt pathways are undergoing clinical trials for MIBC therapy, no drug has yet been approved for BC treatment [32, 34–36]. Here, AKT1 is linked to breast cancer.